Design and synthesis of Leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury
作者:Xiaohe Li、Maodun Xie、Cheng Lu、Jiahe Mao、Yuting Cao、Yuyu Yang、Yujiao Wei、Xinhua Liu、Sheng Cao、Yang Song、Junya Peng、Yunyun Zhou、Qiuyan Jiang、Gang Lin、Shuanglin Qin、Min Qi、Min Hou、Xiang Liu、Honggang Zhou、Guang Yang、Cheng Yang
DOI:10.1016/j.ejmech.2020.112614
日期:2020.10
Existing research revealed that Leukotriene B4 (LTB4) is the critical endogenous molecule to induce neutrophil inflammatory response. LTB4 blocking biosynthesis is the potential strategy treating IPF and ALI. In the present study, 45 hydroxamic acid derivatives were produced, and compound 26 was screened out as a highly selective Lead compound of Leukotriene A4 Hydrolase (LTA4H), i.e., an enzyme critical
特发性肺纤维化(IPF)和急性肺损伤(ALI)被认为是中性粒细胞功能异常的两个严重的公共卫生问题。它们会引起慢性炎症,并与随后的组织损伤有关。在临床实践中已经有稀有药物应用于有效治疗。现有研究表明,白三烯B 4(LTB 4)是诱导中性粒细胞炎症反应的关键内源性分子。阻断LTB 4的生物合成是治疗IPF和ALI的潜在策略。在本研究中,生产了45种异羟肟酸衍生物,并筛选出化合物26作为白三烯A4水解酶(LTA 4)的高选择性铅化合物。H),即对LTB 4的生物合成至关重要的酶。该化合物能够减轻IPF小鼠模型早期的嗜中性粒细胞炎症,并通过LTB 4阻断体内生物合成的机制减轻LPS诱导的急性肺损伤。该化合物是否作为潜在的先导化合物用于治疗IPF和ALI还需要进一步验证。